MARCADORES PREDITIVOS PARA O TRATAMENTO COM INIBIDORES DE EGFR

The present invention provides biomarkers that are predictive for the response to treatment with an EGFR inhibitor in cancer patients. The markers are the genes GBAS, APOH, SCYL3, PMS2CL, PRODH, SERF1A, URG4A and LRRC31.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PAUL DELMAR, PATRICIA MCLOUGHLIN, VERENA LUTZ, BARBARA KLUGHAMMER
Format:	Patent
Sprache:	por
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides biomarkers that are predictive for the response to treatment with an EGFR inhibitor in cancer patients. The markers are the genes GBAS, APOH, SCYL3, PMS2CL, PRODH, SERF1A, URG4A and LRRC31.